EVMN

Evommune, Inc. NYSE Listed Nov 6, 2025

Healthcare ·Biotechnology ·US · evommune.com

$22.56

Mkt Cap $290.4M

52w Low $13.88 44.9% of range 52w High $33.20

50d MA $24.85 200d MA $22.04

P/E (TTM) -11.2x

EV/EBITDA -6.2x

P/B 3.8x

Debt/Equity 0.0x

ROE -33.5%

P/FCF -7.0x

RSI (14) —

ATR (14) —

Beta 2.31

50d MA $24.85

200d MA $22.04

Avg Volume 603.3K

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

SIC Code

2834

CIK (SEC)

1837254

Phone

(925) 247-4487

1841 Page Mill Road · Palo Alto, CA 94304 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.82	-1.43	-74.4%	25.09	-1.0%	+5.6%	-7.1%	-2.5%	-2.5%	-1.8%	—
Dec 11, 2025	AMC	-6.08	-8.07	-32.7%	19.69	-2.1%	-8.5%	-2.1%	-10.0%	+0.4%	-5.7%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Stifel	Initiates	Buy	$54	$23.80	$24.43	+2.6%	+2.9%	-3.6%	+2.2%	-1.4%	-5.6%
Apr 10	RBC Capital	Maintains	Outperform → Outperform	—	$28.65	$28.50	-0.5%	-11.0%	+5.9%	-1.4%	+1.2%	-0.6%
Mar 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.03	$25.30	+1.1%	-3.8%	-2.2%	-1.0%	+0.5%	-10.4%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.99	$29.52	+73.7%	+70.9%	-2.0%	-2.0%	+13.2%	-1.2%

Data updated apr 25, 2026 8:01am · Source: massive.com